ObjectivesTo assess the current health of the Deaf community in the UK and compare with the general population.DesignA quota sample of adult Deaf British Sign Language (BSL) users underwent a health assessment and interview in 2012–2013. Comparative data were obtained from the Health Survey for England (HSE) 2011 and the Quality Outcomes Framework (QOF) 2012.SettingParticipants completed a structured interview and health assessment at seven Bupa centres across the UK, supported in BSL by Deaf advisers and interpreters.Participants298 Deaf people, 20–82 years old, 47% male, with 12% from ethnic minorities.Main outcome measuresSelf–reported health conditions, medication usage, tobacco and alcohol consumption; measured blood pressure (BP), body mass index, fasting blood sugar and lipid profile.ResultsRates of obesity in the Deaf sample were high, especially in those over 65 years, and 48% were in a high risk group for serious illness. High BP readings were obtained in 37% of Deaf people (21% in HSE): 29% were unaware of this (6% in HSE). Only 42% of Deaf people being treated for hypertension had adequate control, compared with 62% of the general population. Deaf people with self-reported cardiovascular disease (CVD) were significantly less than the general population. One-third of Deaf participants had total cholesterol >5 mmol/L but although control rates were high compared with HSE, treatment rates for self-reported CVD were half the general population rate. Eleven per cent of Deaf participants had blood sugar at prediabetic or diabetic levels, and 77% of those at prediabetic levels were unaware of it. Deaf respondents self-reported more depression (31% of women, 14% of men), but less smoking (8%) and alcohol intake (2–8 units/week).ConclusionsDeaf people's health is poorer than that of the general population, with probable underdiagnosis and undertreatment of chronic conditions putting them at risk of preventable ill health.

Radiologists today are under increasing work pressure. We surveyed radiologists in the United States across practice settings, and the overwhelming majority reported an increased workload. Artificial intelligence (AI), which includes machine learning, can help address these issues. It also has the potential to improve clinical outcomes and raise further the value of medical imaging in ways yet to be defined. In this article, we report on recent McKinsey & Company work to understand the growth of AI in medical imaging. We highlight progress in its clinical application, the investments that are backing it, and the barriers to broader adoption. We also offer a view on how the market will develop. AI is set to have a big impact on the medical imaging market and hence on how radiologists work, helping them to speed up scan time, make more accurate diagnoses, and ease their workload. As AI in medical imaging increasingly proves its worth, it is hard to imagine that AI will not ultimately transform radiology.

The medical device industry is undergoing rapid change as innovation accelerates, new business models emerge, and artificial intelligence and the Internet of Things create disruptive possibilities in health care. On the innovation front, global annual patent applications related to medical devices have tripled in 10 years, and technology cycle times have halved in just 5 years. Connectivity has explodedby 2021, the world will have more than three times as many smart connected devices as people-and more and more medical devices and processes contain integrated sensors. In this article, we report on recent McKinsey (McKinsey & Company, New York, New York) work to map start-ups and trends shaping the future of medical imaging. We identify technology clusters with prospects of future growth, look at some of their cutting-edge practices, and consider what the implications may be for our specialty.

No abstract

No abstract